Lipid Disorders
Conference Coverage
HDL hypothesis: New trial expected to show why prior ones failed
NATIONAL HARBOR, MD. – A 17,000-plus–patient trial is focusing on function rather than quantity of HDL in patients thought most likely to benefit...
Feature
Lipidologists welcome bempedoic acid as new lipid-lowering option
Experts see a circumscribed but useful role for the first new class of oral lipid-lowering drug since ezetimibe in 2002.
News
New lipid-lowering drug earns FDA approval
From the Journals
Alcohol use linked to NAFLD
Binge drinking and heightened alcohol consumption were associated with greater risk of hepatic steatosis.
Conference Coverage
How much exercise is needed for maximum heart benefit?
SNOWMASS, COLO. – It’s a lot less than you may think.
From the Journals
Statin, antihypertensive treatment don’t guarantee healthier lifestyles
Data from 41,000 Finns showed that people put on a primary CVD-prevention regimen don’t always turn healthier.
News
New Vascepa indication opens up treatment to millions; “Most significant event since statins”
From the Journals
Carbs, fat, and mortality: Types matter more than levels
From the Journals
Liver fibrosis scores predict CV event risk associated with NAFLD
NAFLD is associated with a twofold increase in cardiovascular events, and liver fibrosis in NAFLD is associated with a fourfold increase.
Conference Coverage
Framingham: Exercise lessens cardiometabolic risk of poor diet
PHILADELPHIA –
Conference Coverage
Nearly 25% of U.S. adults take an obesogenic prescription drug
The 2013-2016 analysis also showed a strong link between obesogenic drug use and increasing obesity severity.